BioSpace News Archive

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial results and pipeline updates on Thursday, November 11, 2021,

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021.

Lucid Diagnostics Inc. today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.

Indivior PLC (LON: INDV) today announced the presentation of new data from multiple posters and presentations at the Canadian Society of Addiction Medicine – La Société Médicale Canadienne sur L’addiction (CSAM-SMCA) 2021 Scientific Conference, taking place virtually October 21-23, 2021 .

Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, today announced that the Company has been invited to present a poster presentation at the sixth biennial Canadian Cancer Research Conference.

Darmiyan CEO Padideh Kamali-Zare achievements are recognized among Top 25 Women Leaders in Biotech 2021 according to Healthcare Tech Outlook magazine’s review.

David Tsur’s 40 years of Biotech experience further strengthens the Board at a critical phase of the Company’s growth.

NuProbe scientists and collaborators recently announced research demonstrating the accurate quantitation of somatic mutations below 0.01% variant allele frequency (VAF).

Kintor Pharmaceutical Limited announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021.